RIPTACs: Reshaping Precision Oncology Beyond PROTACs
Introduction: Targeted induced-proximity therapeutics have transformed drug discovery. PROTACs induce ubiquitin-mediated degradation of disease proteins, whereas RIPTACs selectively eliminate biomarker-positive cells by recruiting essential proteins to disease-specific proteins. Mechanistic Differences PROTACs vs RIPTACs: Figure-1: Mechanism of action- PROTACs vs RIPTACs Detailed Comparison- PROTACs vs RIPTACs: Parameter PROTACs RIPTACs Full Form Proteolysis Targeting Chimera Regulated Induced […]
Fostemsavir (Rukobia®): A Comprehensive Review of Its Antiviral Activity, Medicinal Chemistry, Synthetic Route, and Key Intermediates
Introduction: Fostemsavir is a first-in-class HIV-1 attachment inhibitor approved for heavily treatment-experienced adults with multidrug-resistant HIV-1 infection. It is an orally administered phosphonooxymethyl prodrug that is rapidly converted to the active metabolite, temsavir. Temsavir binds the conserved pocket on the HIV-1 envelope glycoprotein gp120 adjacent to the CD4-binding site, preventing viral attachment to CD4+ T […]
PROteolysis TArgeting Chimeras (PROTACs)- 2 decades of research
